Medexus Pharmaceuticals Inc. (MEDXF)
OTCMKTS
· Delayed Price · Currency is USD
2.240
+0.170 (8.21%)
Dec 24, 2024, 12:32 PM EST
Medexus Pharmaceuticals Income Statement
Financials in millions USD. Fiscal year is April - March.
Millions USD. Fiscal year is Apr - Mar.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2019 - 2015 |
|---|---|---|---|---|---|---|---|
Period Ending | Sep '24 Sep 30, 2024 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 | Mar '21 Mar 31, 2021 | Mar '20 Mar 31, 2020 | 2019 - 2015 |
| Revenue | 104.76 | 113.05 | 108.1 | 76.7 | 79.66 | 55.51 | Upgrade
|
| Revenue Growth (YoY) | -12.15% | 4.59% | 40.93% | -3.71% | 43.52% | 63.91% | Upgrade
|
| Cost of Revenue | 44.15 | 47.99 | 42.33 | 33.03 | 32.18 | 20.92 | Upgrade
|
| Gross Profit | 60.61 | 65.07 | 65.77 | 43.67 | 47.48 | 34.59 | Upgrade
|
| Selling, General & Admin | 41.1 | 44.87 | 48.25 | 44.03 | 36.17 | 30.64 | Upgrade
|
| Research & Development | 0.8 | 1.61 | 2.94 | 5.87 | 4.6 | 1.16 | Upgrade
|
| Operating Expenses | 47.78 | 52.28 | 57.28 | 56.05 | 46.75 | 35.73 | Upgrade
|
| Operating Income | 12.82 | 12.79 | 8.49 | -12.38 | 0.73 | -1.14 | Upgrade
|
| Interest Expense | -9.07 | -13.36 | -13.61 | -12.22 | -9.82 | -6.87 | Upgrade
|
| Interest & Investment Income | - | - | - | - | - | 0.22 | Upgrade
|
| Currency Exchange Gain (Loss) | -0.18 | -0.17 | -1.69 | -0.15 | 1.99 | -1.11 | Upgrade
|
| Other Non Operating Income (Expenses) | 2.76 | 2.84 | 2.64 | 23.55 | -22.3 | 8.01 | Upgrade
|
| EBT Excluding Unusual Items | 6.33 | 2.1 | -4.17 | -1.2 | -29.39 | -0.89 | Upgrade
|
| Merger & Restructuring Charges | -1.46 | -1.11 | -0.88 | -0.87 | -2.11 | -3.96 | Upgrade
|
| Asset Writedown | -3.35 | -0.89 | - | -1.75 | - | -0.69 | Upgrade
|
| Pretax Income | 1.51 | 0.11 | -5.04 | -3.82 | -31.5 | -5.55 | Upgrade
|
| Income Tax Expense | -0.78 | 0.32 | -6.26 | -0.94 | -3.24 | -0.84 | Upgrade
|
| Net Income | 2.3 | -0.21 | 1.22 | -2.88 | -28.26 | -4.7 | Upgrade
|
| Net Income to Common | 2.3 | -0.21 | 1.22 | -2.88 | -28.26 | -4.7 | Upgrade
|
| Shares Outstanding (Basic) | 24 | 22 | 20 | 19 | 15 | 14 | Upgrade
|
| Shares Outstanding (Diluted) | 25 | 22 | 21 | 20 | 15 | 14 | Upgrade
|
| Shares Change (YoY) | 18.66% | 9.56% | 3.36% | 30.65% | 5.83% | 44.92% | Upgrade
|
| EPS (Basic) | 0.09 | -0.01 | 0.06 | -0.15 | -1.86 | -0.33 | Upgrade
|
| EPS (Diluted) | 0.09 | -0.01 | 0.06 | -0.15 | -1.86 | -0.33 | Upgrade
|
| Free Cash Flow | 22.12 | 18.66 | -1.51 | -1.28 | 4.92 | -1.81 | Upgrade
|
| Free Cash Flow Per Share | 0.90 | 0.83 | -0.07 | -0.06 | 0.32 | -0.13 | Upgrade
|
| Gross Margin | 57.85% | 57.56% | 60.84% | 56.94% | 59.60% | 62.32% | Upgrade
|
| Operating Margin | 12.24% | 11.31% | 7.85% | -16.14% | 0.92% | -2.04% | Upgrade
|
| Profit Margin | 2.19% | -0.19% | 1.13% | -3.75% | -35.48% | -8.47% | Upgrade
|
| Free Cash Flow Margin | 21.12% | 16.51% | -1.39% | -1.66% | 6.18% | -3.26% | Upgrade
|
| EBITDA | 18.48 | 18.44 | 14.37 | -6.46 | 6.35 | 2.44 | Upgrade
|
| EBITDA Margin | 17.64% | 16.31% | 13.30% | -8.42% | 7.98% | 4.40% | Upgrade
|
| D&A For EBITDA | 5.66 | 5.66 | 5.88 | 5.92 | 5.62 | 3.58 | Upgrade
|
| EBIT | 12.82 | 12.79 | 8.49 | -12.38 | 0.73 | -1.14 | Upgrade
|
| EBIT Margin | 12.24% | 11.31% | 7.85% | -16.14% | 0.92% | -2.04% | Upgrade
|
| Effective Tax Rate | - | 301.89% | - | - | - | - | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.